Psilocybin PTSD evidence appeared first in an SEC filing, exposing how media, journals and registries show different levels of trial maturity

Psilocybin's evidence for PTSD illustrates why media attention, journal publications and company disclosures can present different pictures of clinical maturity. A JAMA Network Open review found that 43% of sampled news articles named PTSD and 7% claimed symptom reduction, yet its literature search found no peer-reviewed psilocybin PTSD trial by October 2024. Compass Pathways had already disclosed open-label results from a 22-person study in a May 2024 SEC filing, reporting roughly a 30-point CAPS-5 decline by week 4 without a comparison group. A peer-reviewed report followed in 2025, and a second small open-label study appeared in 2026, while Compass's randomized Redefine trial is still recruiting. The broader analysis argues that filings, registries, preprints and journals answer different questions and should be read together rather than treated as interchangeable evidence. Publication counts, news visibility and single-sponsor toplines do not establish an indication's maturity.